Sana Q1 net loss $47.2M, cash $101.1M; Mayo $25M equity; SC451/SG293 trials on track for 2026

Sana Biotechnology, Inc.

• Net loss of $47.2M ($0.17/sh); R&D expenses $28.7M (down from $37.2M YoY).
• Cash & securities $101.1M; pro forma $128.9M including Mayo $25M equity and ATM activity.
• Mayo collaboration to accelerate SC451; Mayo made $25M equity investment with option for another $25M.
• SC451 Phase 1 IND filing expected later this year; SG293 clinical data presented May 12 at ASGCT.
• SG227 (BCMA CAR) expected to begin clinical testing as early as mid-2027, contingent on SG293 data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.